Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease

Abstract

Mutations in the glucocerebrosidase (GBA) gene contribute significantly to the clinical landscape of Parkinson’s disease, often manifesting in early-onset symptoms and distinct therapeutic responses among diverse ethnic cohorts. Beyond genetic factors, the management of the disease through deep brain stimulation (DBS) and pharmacological intervention introduces complex neuropsychiatric outcomes. Subthalamic nucleus DBS can induce potent, “morphine-like” euphoric sensations, potentially leading to compulsive self-stimulatory behaviors as patients seek to replicate reward-related responses. This phenomenon suggests that stimulation may inadvertently affect adjacent limbic or mesolimbic pathways. Similarly, dopaminergic therapies—specifically dopamine agonists—are linked to the sudden augmentation of artistic productivity characterized by an obsessive-compulsive quality. While such increases in creative output may appear beneficial, they frequently occur alongside broader behavioral disinhibition and hypersexuality, reflecting the impact of dopaminergic stimulation on frontal-limbic circuits. These clinical observations highlight the necessity of monitoring for addictive and impulsive behaviors in patients undergoing advanced surgical or medical treatments for Parkinson’s disease. – AI-generated abstract.